Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
Efforts underway to accelerate patient recruitment and amend protocols to improve patient outcomes. Interim data readouts for both studies anticipated in H2 2023. Press release BOSTON — March 28, 2023 – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity …